Rethinking remdesivir for COVID-19: A Bayesian reanalysis of trial findings.

Joyce M HoekSarahanne M FieldYmkje Anna de VriesMaximilian LindeMerle-Marie PittelkowJasmine MuradchanianDon van Ravenzwaaij

Published in: PloS one (2021)

We recommend that regulatory bodies take all available evidence into account for endorsement decisions. A Bayesian approach can be beneficial, in particular in case of statistically non-significant results. This is especially pressing when limited clinical efficacy data is available.

Keyphrases

coronavirus disease
sars cov
study protocol
phase iii
electronic health record
clinical trial
transcription factor
phase ii
machine learning
data analysis
artificial intelligence